<DOC>
	<DOCNO>NCT03002233</DOCNO>
	<brief_summary>This study 2-part study . Part A single-dose , open-label study design determine PK , safety tolerability 5 μg TRK-820 oral administration subject end-stage renal disease ( ESRD ) require hemodialysis . Part B multiple dose , open-label study design determine PK , PD , safety tolerability multiple dose subject ESRD require hemodialysis refractory uremic pruritus ( UP ) . Each subject receive 3 dos TRK-820 ( 2.5 , 5 10 μg ) .</brief_summary>
	<brief_title>TRK-820 Study Subjects Hemodialysis With Without Uremic Pruritus</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<criteria>Adult nonsmoking male female subject ( ≥ 18 year age ) ESRD require hemodialysis , least 3 time week . Subjects clinical diagnosis UP , uncontrolled current medication treatment . ( Part B ) Subject know hypersensitivity opioids ingredient study medication . Subject pruritus relate ESRD ( i.e. , UP ) . ( Part B )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>TRK-820</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Uremic Pruritus</keyword>
</DOC>